Back to Search Start Over

Bavarian Nordic reports 12-month durability data from Phase 2 COVID-19 booster vaccine trial

Source :
M2 Pharma. June 16, 2023
Publication Year :
2023

Abstract

M2 PHARMA-June 16, 2023-Bavarian Nordic reports 12-month durability data from Phase 2 COVID-19 booster vaccine trial (C)2023 M2 COMMUNICATIONS Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) on Friday released the [...]

Subjects

Subjects :
Bavarian Nordic A/S -- Product development
Biological products industry -- Product development
Clinical trials
Vaccines -- Product development
Pharmaceutical industry -- Product development
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.753154792

Tools

Authors Abstract Subjects Details